Drugs / RISLENEMDAZ
RISLENEMDAZ
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00472576 | May 2007 → Aug 2009 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 1 | NCT00505843 | May 2007 → Feb 2008 | Parkinson disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02459236 | Jun 2015 → Sep 2016 | major depressive disorder | Avalo Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01941043 | Nov 2013 → Sep 2014 | major depressive disorder | Avalo Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RISLENEMDAZ | ChEMBL registry synonym — accepted as the source's own label CHEMBL2068839 ↗ |
| Known as | CERC-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01941043 ↗ |
| Known as | MK-0657 | “Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate...” PMID 19491335 ↗ Jun 2009 |
| Action | Inhibit | “selective NR2B antagonist (MK-0657, 4-8 mg/day given orally)” NCT00472576 ↗ |
| Modality | Small molecule | — CHEMBL2068839 ↗ |
| Route | Oral | “MK-0657, 4-8 mg/day given orally” NCT00472576 ↗ |